

Paper No. ___
Filed: July 1, 2014

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ANTARES PHARMA, INC., LEO PHARMA A/S and LEO PHARMA INC.,

Petitioners

v.

MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRÄPARATE MBH

Patent Owner

Case No.: Not yet assigned
Patent No. 8,664,231
Title: Concentrated Methotrexate Solutions

**PETITION FOR *INTER PARTES* REVIEW
OF U.S. PATENT NO. 8,664,231**

Table of Contents

I.	Introduction.....	1
II.	Grounds for Standing.....	1
III.	Mandatory Notices	1
	A. Real Party-In-Interest.....	1
	B. Related Matters	1
	C. Lead and Back-Up Counsel, and Service Information	1
IV.	Payment of Fees.....	2
V.	Identification of Challenge	2
	A. Overview of the '231 Patent	2
	1. The '231 Specification	2
	2. The '231 Claims.....	3
	3. The '231 Prosecution History	6
	B. Claim Construction of Challenged Claims.....	9
	1. “Subcutaneously”	9
	2. “Pharmaceutically acceptable solvent”	9
	3. “Injection device”	10
	4. “Ready-made syringe”	10
	5. “Pen injector”	10
	C. Statement of Precise Relief Requested for Each Claim Challenged	10
	1. Claims for Which Review Is Requested.....	10
	2. Statutory Grounds of Challenge	10
	D. Overview of the Cited Art.....	12

E.	Level of Skill in the Art.....	14
VI.	Detailed Explanation of the Challenge.....	15
A.	Ground 1: U.S. Patent 6,544,504 (“ <i>Grint;</i> ” Ex. 1003) anticipates claims 1, 2, 4, 5, 6, 11, 12, 13, 17, and 22 under 35 U.S.C. § 102(b).	15
1.	Claim chart for Ground 1.....	18
B.	Ground 2: Claims 7, 8, 9, 10, 14, 15, 16, 19, 20, and 21 are rendered obvious by U.S. Patent 6,544,504 (“ <i>Grint;</i> ” Ex. 1003) in view of <i>Insulin Admin.</i> (Ex. 1015).....	22
1.	Claim chart for Ground 2.....	24
C.	Ground 3: Claim 18 is rendered obvious by U.S. Patent 6,544,504 (“ <i>Grint;</i> ” Ex. 1003) in view of <i>Alsufyani</i> (Ex. 1006).	27
1.	Claim chart for Ground 3.....	28
D.	Grounds 4-6: Claims 1-22 are obvious under 35 U.S.C. § 103(a) over primary references <i>the PDR for Mexate</i> [®] (Ex. 1007) or <i>Hospira</i> (Ex. 1009) and <i>Brooks</i> (Ex. 1008), further in view of <i>Insulin Admin.</i> (Ex. 1015) and <i>Alsufyani</i> (Ex. 1006).....	28
1.	Discussion of the primary references.....	28
a.	The primary reference “ <i>the PDR for Mexate</i> [®] ” teaches MTX at concentrations between 2 and 125 mg/ml for intramuscular injection to treat psoriasis.....	28
b.	The primary reference “ <i>Hospira</i> ” teaches 100 mg/ml MTX for intramuscular injection to treat psoriasis.....	30
c.	The primary reference <i>Brooks</i> (Ex. 1008) teaches that intramuscular and subcutaneous injections of MTX are interchangeable.....	31
2.	Ground 4: Claims 1-5, 11, 12, 13, 17, and 22 of the ’231 patent are obvious over <i>the PDR for Mexate</i> [®] (Ex. 1007) or <i>Hospira</i> (Ex. 1009) in view of <i>Brooks</i> (Ex. 1008).....	32
a.	Claim chart for Ground 4 showing exemplary citations in <i>the PDR for Mexate</i> [®] (Ex. 1007).....	34

b.	Claim chart for ground 4 showing exemplary citations in <i>Hospira</i> (Ex. 1009).....	37
c.	Claim chart for ground 4 showing exemplary citations in <i>Brooks</i> (Ex. 1008)	39
3.	Ground 5: Claims 7-10, 14-16, and 19-21 are rendered obvious by <i>the PDR for Mexate</i> [®] (Ex. 1007) or <i>Hospira</i> (Ex. 1009) and <i>Brooks</i> (Ex. 1008), in view of <i>Insulin Admin.</i> (Ex. 1015).....	41
E.	Grounds 6-8: Claims 1-22 are rendered obvious by primary references <i>Hoekstra</i> (Ex. 1004) and <i>Jørgensen</i> (Ex. 1005), further in view of <i>Insulin Admin.</i> (Ex. 1015) and secondary reference <i>Alsufyani</i> (Ex. 1006).....	43
1.	Discussion of the Primary References	43
a.	The primary reference <i>Hoekstra</i> (Ex. 1004) teaches subcutaneous administration of MTX at high doses.....	43
b.	The primary reference <i>Jørgensen</i> (Ex. 1005) teaches that the volume of subcutaneously injected solutions should be formulated to contain less than one milliliter (mL).....	43
2.	Ground 6: Claims 1-6, 11, 12, 13, 17, and 22 are rendered obvious by <i>Hoekstra</i> (Ex. 1004) and <i>Jørgensen</i> (Ex. 1005).....	45
a.	Claim chart for Ground 6 showing exemplary citations in <i>Hoekstra</i> (Ex. 1004) and <i>Jørgensen</i> (Ex. 1007).....	46
3.	Ground 7: Claims 7-10, 14-16, and 19-21 are rendered obvious by <i>Hoekstra</i> (Ex. 1004) and <i>Jørgensen</i> , in view of <i>Insulin Admin.</i> (Ex. 1015).....	49
4.	Ground 8: Claim 18 is rendered obvious by <i>Hoekstra</i> (Ex. 1004) and <i>Jørgensen</i> (Ex. 1005), in view of secondary reference <i>Alsufyani</i> (Ex. 1006).....	50
F.	Secondary Considerations Do Not Rebut the <i>Prima Facie</i> Case of Obviousness.....	51

1.	Any toxicity associated with MTX after subcutaneous injection is dose, not concentration dependent.	52
2.	The bioavailability of MTX after subcutaneous injection is dose, not concentration, dependent.	55
3.	Applicant’s evidence of unexpected results is not based on a comparison of the claimed invention to the closest prior art.	57
4.	<i>Zackheim</i> Does Not Teach Away From the Claimed Invention.....	59
VII.	Conclusion	60

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.